cardiovascular diseases Cardiovascular surgery
Conditions
Interventions
Isoflurane group: Isoflurane infusion starts 3 ml/hr to Anesthetic Conserving Device. Isoflurane infusion is adjusted between 0 to 7 ml/hr, end tidal isoflurane concentration 0 to 1 % to achieve targe
Sponsors
Hakozaki Takahiro
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Informed consent obtained from the patient 2. Patirnt over 18 years at the time of imformed consent 3. patient undergoing scheduled cardiovasclar surgery 4. patient who are schedulled to receive mechanical ventilation after surgery 5. Ventilatory weaning expected in more than 2 hours but less than 48 hours 6. Patient who are not receiving mechamical cirulatory support 7. Patient who are not receiving renal replacement therapy
Exclusion criteria
Exclusion criteria: 1. Patient with history of malignant hyperthermia or a family history of malignant hyperthremia 2. Diagnosed moderate chronic respitatory failure 3. Diagnosed moderate chronic heart failure 4. Diagnosed moderate chronic kidney disease 5. Patient who are receiving or schedulled to receive mechanical circulatory support 6. Patient judged to be inappropriate for inclusion
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Geometric mean of the percentage of eccessive mean tidal volume (over 8 ml/kg PBW) every 5 minutes during the first 2 hours after sedation. | — |
Secondary
| Measure | Time frame |
|---|---|
| Number of ventilator setting adjustments, asynchrony rate, time not achieving target sedation level, duration of ventilation, cumulative opioid dose, cumulative cathecholamine dose, troponin I change rate, presence of delirium, acute kidney injury, P/F ratio change rate, liver injury, nausea/vomiting, ICU stay, 28-day mortality | — |
Contacts
Public ContactTakahiro hakozaki
Fukusima Medical University Hospital
Outcome results
None listed